RNA technology Archives

News and Trends 20 Jul 2022

ICL and PlantArcBio look to use RNAi to boost crop yields

ICL, a global specialty minerals company, and ag-biotech company PlantArcBio, Ltd., have announced the development of a novel bio-stimulant technology platform to improve crop yields while having a minimal impact on the environment. The platform uses RNAi (RNA interference) technology to maximize a plant’s natural yield increase mechanisms, without any genetic modification, and was the […]

July 20, 2022 - 2 minutesmins - By Jim Cornall

beta-thalassemia blood APS antiphospholipid syndrome

News and Trends 11 Jul 2022

Study results reveal bleeding episodes are significantly reduced by hemophilia drug

People suffering from a severe blood disorder may only have to take a once-monthly drug following successful results from an ongoing study. Global healthcare company, Sanofi, has been conducting a study into fitusiran prophylaxis and results have shown it reduces bleeds by 61 per cent in people with hemophilia A or B, with or without […]

July 11, 2022 - 4 minutesmins - By Liza Laws

News and Trends 21 Jun 2022

Therorna funding to accelerate circRNA-based platform

Therorna Inc., a Chinese biotech company specializing in the development of circular RNA (circRNA) technology-based new vaccines and therapies, including for COVID-19, has completed a $42 million series A financing round. The funding was co-led by MSA Capital, with participation from Sherpa Healthcare Partners, 3H Health Investment, and existing investors Quan Capital and Cenova Capital. […]

June 21, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 9 Jun 2022

Ziphius Vaccines and University of Antwerp to work on RNA-based delivery methods

Belgian biopharma firm Ziphius Vaccines is set to collaborate with the University of Antwerp to research and develop a lipid library for optimized delivery systems of self-amplifying RNA-based drugs (saRNA) and therapeutics. Messenger RNA (mRNA) vaccines deliver genetic instructions to cells to create proteins that then train the immune system against a pathogen, such as […]

June 9, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 9 Jun 2022

Amaroq Therapeutics ‘hits early milestones’ in cancer treatment

New Zealand biotech company Amaroq Therapeutics said it is progressing towards clinical trials following a promising initial development phase. The company, a start-up spun out of the University of Otago, is focused on developing a new class of therapeutics that target long non-coding RNAs (lncRNA) in cancer. Sarah Diermeier, chief scientific officer and founder of […]

June 9, 2022 - 2 minutesmins - By Jim Cornall

covid 19 vaccine patent waiver intellectual property ip

News and Trends 15 Jun 2021

Patent Waiver on Covid-19 Vaccines Splits Opinions in Biotech Industry

Attempts to increase global Covid-19 vaccine coverage with a temporary patent waiver have been met with hostility from many big pharma and biotech companies, but some smaller players welcome the idea. With the Covid-19 pandemic still rampaging through many countries and new viral variants popping up with alarming regularity, scuffles over who holds intellectual property […]

June 15, 2021 - 5 minutesmins - By Anita Chakraverty

In Depth 1 Mar 2021

How Are European Biotechs Tackling the Cardiovascular Disease Problem?

Cardiovascular diseases may not regularly grab the headlines, but they’re the leading cause of mortality globally, making up over 30% of all deaths worldwide. While there are many established treatments on the market, there’s still a need for more effective treatments – can biotech companies provide the answer? We all know that frequent exercise, a […]

March 1, 2021 - 9 minutesmins - By Farhan Mitha

Best in Biotech 28 Dec 2020

A Year to Remember: The Biggest European Biotech News in 2020

The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled through. Let’s look back at some of the top moments in the last 12 months. After the many drug approvals, startup foundations, and venture capital highs we saw in 2019, it looked like 2020 was going to be a comfortable […]

December 28, 2020 - 12 minutesmins - By Jonathan Smith

News and Trends 26 Mar 2020

Silence Therapeutics to Work with AstraZeneca in RNAi Deal Worth up to €3.6B

AstraZeneca is recruiting RNAi specialist Silence Therapeutics to develop treatments for cardiovascular, renal, metabolic, and respiratory diseases. RNA interference, or RNAi, is a relatively new field of medicine in which therapeutic small interfering (si)RNA molecules — known as siRNA molecules — can selectively block genes and thus inhibit the production of disease-causing proteins. John Strafford, […]

March 26, 2020 - 3 minutesmins - By Laura Cowen

News and Trends 3 Mar 2020

Alnylam Gets Second RNAi Drug Approval from EMA

US biotech Alnylam Pharmaceuticals has succeeded in getting its second RNAi drug — for treatment of rare, inherited liver diseases — approved by the European Medicines Authority just months after achieving US FDA approval for the same drug. Alnylam are well known for being pioneers in the RNA interference space. The company achieved the first […]

March 3, 2020 - 2 minutesmins - By Helen Albert

News and Trends 3 Feb 2020

CureVac Bids to Develop First mRNA Coronavirus Vaccine

RNA vaccine developer CureVac will receive a grant of up to €8.3M from a global partnership to develop an mRNA vaccine against the new coronavirus strain from China. The agreement follows on from an existing collaboration launched in 2019, when the Coalition for Epidemic Preparedness Innovations, or CEPI, granted CureVac €30M to develop facilities that […]

February 3, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 7 Jan 2020

AstraZeneca Recruits RNA Biotech to Develop Metabolic Disease Therapies

The UK biotech MiNA Therapeutics has launched a collaboration with AstraZeneca to develop small activating RNA drugs, which could treat metabolic diseases using targets unreachable by current medications. According to the agreement, the two partners will carry out preclinical research with the aim of generating candidate drugs based on small activating RNA, or saRNA — […]

January 7, 2020 - 2 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us